Business Description
Pieris Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7207951036
Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.15 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.46 | |||||
| Debt-to-EBITDA | -1.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.87 | |||||
| Beneish M-Score | 2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.1 | |||||
| 3-Year EBITDA Growth Rate | 41.6 | |||||
| 3-Year EPS without NRI Growth Rate | 44.6 | |||||
| 3-Year FCF Growth Rate | 12.4 | |||||
| 3-Year Book Growth Rate | -21.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.08 | |||||
| 9-Day RSI | 21.47 | |||||
| 14-Day RSI | 29.3 | |||||
| 6-1 Month Momentum % | -38.11 | |||||
| 12-1 Month Momentum % | -80.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | |||||
| Quick Ratio | 3.24 | |||||
| Cash Ratio | 2.21 | |||||
| Days Sales Outstanding | 16.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.9 | |||||
| Shareholder Yield % | -140.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -28.57 | |||||
| Net Margin % | -57.33 | |||||
| FCF Margin % | -126.12 | |||||
| ROE % | -86.94 | |||||
| ROA % | -33.77 | |||||
| ROIC % | -35.72 | |||||
| ROC (Joel Greenblatt) % | -60.8 | |||||
| ROCE % | -29.3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.3 | |||||
| PB Ratio | 0.5 | |||||
| Price-to-Tangible-Book | 0.5 | |||||
| EV-to-EBIT | 1.07 | |||||
| EV-to-EBITDA | 1.27 | |||||
| EV-to-Revenue | -0.3 | |||||
| EV-to-FCF | 0.23 | |||||
| Price-to-Net-Current-Asset-Value | 0.51 | |||||
| Price-to-Net-Cash | 0.95 | |||||
| Earnings Yield (Greenblatt) % | 93.46 | |||||
| FCF Yield % | -400.52 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers